TGF-Beta: a Master Switch in Tumor Immunity
The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
The capacity of the immune system to distinguish foreign from self-antigen, and to subsequently eliminate the threat of disease without injuring the host is crucial for survival. It also serves to defend against tumor formation and progression via a process termed cancer immunosurveillance. Innate and adaptive immune cell types and effector molecules collectively function as extrinsic tumorsuppressor mechanisms. However, tumors may escape immunesurveillance through a variety of mechanisms that create a local microenvironment that is unfavorable for effective tumor immunity. Transforming growth factor β (TGF-β) has pleiotropic effects on the immune system, and is recognized as one of the most potent immunosuppressive agents in facilitating oncogenesis. The TGF-β pathway promotes cancer progression by concomitantly enhancing tumor metastases while inhibiting the protective host immunity. In this review, we discuss mechanisms through which TGF-β interferes with the development of an anti-tumor immunity and potential means through which to circumvent its activity in order to define more effective cancer immunotherapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TGFβ is a key suppressive cytokine normally produced by immune cells but which can be co-opted by tumors to suppress effective immune responses (Batlle and Massagué, 2019; Gigante et al., 2012).”
From Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies (2020) · cites this paper as Gigante et al., 2012
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 2×
“2010; 184: 6556 [114] Bettelli E, Carrier Y, Gao W, et al.”
BackgroundMyeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,857
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265 · cited 2×
“Th17 cells produce IL-17, which is a potent inflammatory cytokine that impacts a variety of cell types including fibroblasts, endothelial cells, and epithelial cells to induce the expression of additional inflammatory cytokines, such as IL-6, TNF, G-CSF, chemokines, and matrix metalloproteases, all of which coordinate…”
Background
Cited by
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
Poniatowski, Ł. A., Wojdasiewicz, P., Gasik, R., & Szukiewicz, D. (2015) · Mediators of Inflammation · doi:10.1155/2015/137823 · Cited by 281
Krstić, J., Trivanović, D., Mojsilović, S., & Santibanez, J. F. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/654594 · Cited by 225
Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
Roth, T. L., Li, P. J., Blaeschke, F., Nies, J. F., Apathy, R., Mowery, C., Yu, R., Nguyen, M. L. T., Lee, Y., Truong, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.039 · Cited by 186
Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
Zhong, X., Zhang, H.-T., Zhu, Y., Liang, Y., Yuan, Z., Li, J., Li, X., Li, X., Jia, Y., Tian, H., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1141-9 · Cited by 144
Yu, Z., Zhao, H., Feng, X., Li, H., Qiu, C., Yi, X., Tang, H., & Zhang, J. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.05.027 · Cited by 124
Immunosuppressive Mechanisms of Regulatory Dendritic Cells in Cancer
Shurin, G. V., Ma, Y., & Shurin, M. R. (2013) · Cancer Microenvironment · doi:10.1007/s12307-013-0133-3 · Cited by 114
The human papillomavirus E7 oncoprotein as a regulator of transcription
Songock, W. K., Kim, S., & Bodily, J. M. (2016) · Virus Research · doi:10.1016/j.virusres.2016.10.017 · Cited by 109
Abate‐Daga, D., Hanada, K., Davis, J. L., Yang, J. C.-H., Rosenberg, S. A., & Morgan, R. A. (2013) · Blood · doi:10.1182/blood-2013-04-495531 · Cited by 101
Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy
Fendl, B., Berghoff, A. S., Preusser, M., & Maier, B. (2023) · ESMO Open · doi:10.1016/j.esmoop.2022.100776 · Cited by 54
Is immunotherapy here to stay in multiple myeloma?
Rodríguez‐Otero, P., Paiva, B., Engelhardt, M. M., Prósper, F., & Miguel, J. F. S. (2017) · Haematologica · doi:10.3324/haematol.2016.152504 · Cited by 52
Toll-Like Receptor 4 as an Immune Receptor AgainstMycobacterium tuberculosis: A Systematic Review
Sepehri, Z., Kiani, Z., Kohan, F., & Ghavami, S. (2018) · Laboratory Medicine · doi:10.1093/labmed/lmy047 · Cited by 38
Hypothermic microenvironment plays a key role in tumor immune subversion
Du, G., Liu, Y., Li, J., Liu, W., Wang, Y., & Li, H. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.06.018 · Cited by 34
Qazilbash, M. H., Saini, N. Y., Cha, S.-C., Wang, Z., Stadtmauer, E. A., Baladandayuthapani, V., Lin, H. Y., Tross, B., Honhar, M., Rao, S. S., et al. (2021) · Blood · doi:10.1182/blood.2020008493 · Cited by 26
Hypoxia induces calpain activity and degrades SMAD2 to attenuate TGFβ signaling in macrophages
Cui, W., Zhou, J., Dehne, N., & Brüne, B. (2015) · Cell & Bioscience · doi:10.1186/s13578-015-0026-x · Cited by 24
The TGF ‐β‐induced up‐regulation of NKG 2 DL s requires AKT / GSK ‐3β‐mediated stabilization of SP 1
Chen, X., Lu, L., Ke, H., Liu, Z., Wang, H., Wei, W., Qi, Y., Wang, H., Cai, S., & Du, J. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13025 · Cited by 20
Identification of Inhibitors of Thrombospondin 1 Activation of TGF-β
Suto, M. J., Gupta, V. V., Mathew, B., Zhang, W., Pallero, M. A., & Murphy-Ullrich, J. E. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00540 · Cited by 19
Controversial roles played by toll like receptor 4 in urinary bladder cancer; A systematic review
Afsharimoghaddam, A., Soleimani, M., Lashay, A., Dehghani, M., & Sepehri, Z. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.06.013 · Cited by 19
Role of Natural Killer Cells in HIV-Associated Malignancies
Leal, F. E., Premeaux, T. A., Abdel‐Mohsen, M., & Ndhlovu, L. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00315 · Cited by 18
The role of transforming growth factor β in cervical carcinogenesis
Trugilo, K. P., Cebinelli, G. C. M., Castilha, E. P., da Silva, M. R., Berti, F. C. B., & de Oliveira, K. B. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.10.006 · Cited by 17
Lu, Z., Ding, L., Ding, H., Hao, F., Pu, Y., Wang, Y., Chen, S., Yang, Y. T., Zhao, X., Huang, X., et al. (2019) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12888 · Cited by 17
Xu, S., Ware, K. E., Ding, Y., Kim, S. Y., Sheth, M. U., Rao, S. R., Chan, W., Armstrong, A. J., Eward, W. C., Jolly, M. K., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020205 · Cited by 17
The effect of CT26 tumor-derived TGF-β on the balance of tumor growth and immunity
Owyang, S. Y., Zhang, M., Walkup, G. A., Chen, G. E., Grasberger, H., Zaatari, M. E., & Kao, J. Y. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.08.024 · Cited by 16
Han, B., Fang, T., Zhang, Y., Zhang, Y., Gao, J., & Xue, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.920599 · Cited by 13
Cagnin, M., Biasiolo, A., Martini, A., Ruvoletto, M., Quarta, S., Fasolato, S., Angeli, P., Fassina, G., & Pontisso, P. (2019) · Scientific Reports · doi:10.1038/s41598-019-56633-2 · Cited by 12
Liu, B., Xing, L., Liu, S., Sun, L., Su, F., Cui, W., & Jiang, C. (2024) · Frontiers in Marine Science · doi:10.3389/fmars.2024.1334761 · Cited by 12
Ohtani, H., Terashima, T., & Sato, E. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2336-y · Cited by 11
Amerizadeh, F., Bahrami, A., Khazaei, M., Hesari, A., Rezayi, M., Talebian, S., Maftouh, M., Moetamani‐Ahmadi, M., Seifi, S., Shahidsales, S., et al. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27831 · Cited by 11
Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma
Rafei, H., Haroun, F., & Tabbara, I. A. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000506 · Cited by 10
Amano, H., Eshima, K., Ito, Y., Nakamura, M., Kitasato, H., Ogawa, F., Hosono, K., Iwabuchi, K., Uematsu, S., Akira, S., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac137 · Cited by 8
Biomaterials for cancer immunotherapy
Alhallak, K., Sun, J., Muz, B., & Azab, A. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102983-1.00018-1 · Cited by 5
Osipov, A. V., Terpinskaya, T. I., Kuznetsova, T., Ryzhkovskaya, E. L., Lukashevich, V., Rudnichenko, J., Сергеевич, У. В., Starkov, V. G., & Utkin, Y. N. (2017) · Toxins · doi:10.3390/toxins9090274 · Cited by 5
Mojsilović, S. S., & Santibanez, J. F. (2015) · Cell Biology International · doi:10.1002/cbin.10435 · Cited by 5
Myeloid-Derived Suppressor Cells in Tumor-Induced T Cell Suppression and Tolerance
Serafini, P., & Bronte, V. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8056-4_4 · Cited by 3
Zheng, L., Zhang, J., Lei, P., Li, Y., Mu, S., Li, J., Jiang, Y., Qu, F., & Tan, W. (2026) · ACS Nano · doi:10.1021/acsnano.5c19052 · Cited by 2
Mojsilović, S. S., Mojsilović, S. B., Bjelica, S., & Santibanez, J. F. (2018) · Analytical Cellular Pathology · doi:10.1155/2018/3134102 · Cited by 2
Understanding wound healing and cancer in the skin
Tan, M. W. Y. (2020) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/142075 · Cited by 1
Mortara, L., Baci, D., Coco, G., Poggi, A. D., & Bruno, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00014-x · Cited by 1
Castanheira, T. L. L. (2013) · Americanae (AECID Library) · Cited by 1
Melanoma Brain Metastasis: Insights, Progress, Challenges, and Opportunities
Fischer, G. M., & Davies, M. A. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_44-1 · Cited by 1
Activation of T regulatory cells in Type II Immune Responses
Rakesh, P. (2024) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/30750 · Cited by 1
The role of fibroblasts in cancer progression, therapy resistance and field cancerization
Chan, J. S. K. (2017) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/72335
Verma, Y. K., Yadav, N., Kumar, S., & Gangenahalli, G. U. (2021) · Research Square · doi:10.21203/rs.3.rs-885452/v1
Monocyte-Macrophage Lineages in Cancer: Biology, Plasticity, and Therapeutic Targeting
Owusu, C., & Moles, R. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i2.23
Melanoma Brain Metastasis: Insights, Progress, Challenges, and Opportunities
Fischer, G. M., & Davies, M. A. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7147-9_44
BindingDB Entry 50010761: Identification of Inhibitors of Thrombospondin 1 Activation of TGF-β.
BindingDB (2021) · UC San Diego · doi:10.7270/q2m330bv
Mohammad, S. (2022) · Nottingham ePrints (University of Nottingham)
Sea cucumbers: the sustainability of emergent and historical resources
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-6124-9
Naseri, B., Masoumi, J., Abdolzadeh, S., Abedimanesh, S., Baghbani, E., Hatami‐Sadr, A., Heris, J. A., Shanehbandi, D., Akbari, M., Vaysi, S., et al. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4067
Han, B., Fang, T., Zhang, Y., Zhang, Y., Gao, J., & Xue, Y. (2022) · doi:10.3389/fonc.2022.920599.s007
Le mélanome et les polymorphismes associés au dysfonctionnement du système immunitaire
Naso, S. (2012) · IRIS
Análise dos polimorfismos rs1800470 e rs1800471 do TGFB1 em mulheres HPV positivas e controles
Trugilo, K. P. (2016) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Liu, B., Xing, L., Liu, S., Sun, L., Su, F., Cui, W., & Jiang, C. (2024) · doi:10.3389/fmars.2024.1334761.s001
Metadata
- Authors
- Gigante, M., Gesualdo, L., & Ranieri, E.
- Affiliations
- University of Foggia (IT)
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-09-01
- Volume
- 18
- Issue
- 27
- Pages
- 4126-4134
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2055370220
- Cited by
- 45
- References
- 121
- Citations by year
- 2026: 2 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 6 · 2016: 2 · 2015: 4 · 2014: 1 · 2013: 5
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- TGF-beta, antitumor immunity, tumor surveillance, immunosuppression, tumor microenvironment, metastasis, cancer immunotherapy, immune evasion, carcinogenesis
- MeSH terms
- Animals, Humans, Immunity, Innate, Immunologic Surveillance, Neoplasm Metastasis, Neoplasms, Transforming Growth Factor beta, Disease Progression, Adaptive Immunity, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.